| Expression pattern: |
UP |
| Associated gene: |
Ago2, EGFR, AKT, ERK, SHP2 |
| Associated microRNA: |
miR-186 |
| Biological function: |
promotes osimertinib resistance, inhibits apoptosis, and activates EGFR signaling in NSCLC cells |
| Molecular mechanism: |
Exosomal circPLK1 sponges miR-186 (Ago2-dependent), leading to activation of EGFR/AKT/ERK and PI3K/AKT signaling and increased anti-apoptosis, thereby promoting osimertinib resistance. |
| Biological pathway or process: |
PI3K/AKT (promotes); ERK (promotes); apoptosis (inhibits); drug resistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; CCK8; Annexin V/PI Flow Cytometry; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
- |
| Description: |
TAM (M2-polarized macrophage)-derived exosomal circPLK1 is transferred into NSCLC cells and promotes resistance to osimertinib. Mechanistically, circPLK1 binds/sponges miR-186 (Ago2-dependent), leading to increased EGFR/AKT/ERK phosphorylation and activation of PI3K/AKT signaling, thereby suppressing apoptosis under OSI treatment. |
| Confidence score: |
0.7586 |